Zydus Cadila receives USFDA approval to market anti-viral drug
The company has said that the drug, which falls under the anti-viral segment, will be produced at its formulation manufacturing facility in SEZ, Ahmedabad.
The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-2004; an Abbreviated New Drug Application (ANDA) is an application for a US generic drug approval for an existing licensed medication or approved drug.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
